---
title: "White House Announces ‘TrumpRx’ Drug-Buying Site, and Pricing Deal With Pfizer"
description: "The company said it gains a three-year grace period to exempt it from national security-related tariffs."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259586888.md"
published_at: "2025-09-30T18:10:11.000Z"
---

# White House Announces ‘TrumpRx’ Drug-Buying Site, and Pricing Deal With Pfizer

> The company said it gains a three-year grace period to exempt it from national security-related tariffs.

The company said it gains a three-year grace period to exempt it from national security-related tariffs.

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study | Pfizer Inc. (PFE) is launching a new observational study in Taiwan to evaluate the effectiveness of its multiple myeloma | [Link](https://longbridge.com/en/news/276252273.md) |
| What's Driving the Market Sentiment Around Pfizer? | Pfizer's PFE short interest as a percent of float has fallen 9.0% since its last report. According to exchange reported  | [Link](https://longbridge.com/en/news/258741671.md) |
| 08:20 ETFixure Launches on Product Hunt to Introduce Layer-5 Security Decision Intelligence | Fixure has launched its Layer-5 Security Decision Intelligence platform on Product Hunt, inviting security teams to join | [Link](https://longbridge.com/en/news/276059323.md) |
| Pfizer shakes hands with White House on drug discounts under MFN programme | Pfizer has become the first pharmaceutical company to reach an agreement with the US government under the Most Favored N | [Link](https://longbridge.com/en/news/259654914.md) |
| Why Pfizer (PFE) Stock Is Trading Higher Today? | Pfizer's stock rose approximately 3% following reports of a White House initiative to sell discounted prescription drugs | [Link](https://longbridge.com/en/news/259585748.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.